Výsledky vyhledávání - "Lita Fernandez"

Advanced Phase I/II Studies of Targeted Gene Delivery In Vivo: Intravenous Rexin-G for Gemcitabine-resistant Metastatic Pancreatic Cancer

Autor: Victoria S. Chua, Erlinda M. Gordon, Sant P. Chawla, Dorris Quon, Lita Fernandez, William C. Blackwelder, Frederick L. Hall

Publikováno v: Molecular Therapy

Rexin-G, a nonreplicative pathology-targeted retroviral vector bearing a cytocidal cyclin G1 construct, was tested in a phase I/II study for gemcitabine-resistant pancreatic cancer. The patients received escalating doses of Rexin-G intravenously from

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ccbb47283cd1ff1180915644f9604139

Zobrazit plný text záznamu

Phase I/II and Phase II Studies of Targeted Gene Delivery In Vivo: Intravenous Rexin-G for Chemotherapy-resistant Sarcoma and Osteosarcoma

Autor: Doris Quon, Andreh Saralou, Lita Fernandez, William C. Blackwelder, Victoria S. Chua, Erlinda M. Gordon, Frederick L. Hall, Sant P. Chawla

Publikováno v: Molecular Therapy: the Journal of the American Society of Gene Therapy

Rexin-G, a pathotropic nanoparticle bearing a cytocidal cyclin G1 construct was tested in a phase I/II study for chemotherapy-resistant sarcomas and a phase II study for chemotherapy-resistant osteosarcoma. Twenty sarcoma patients and 22 osteosarcoma

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7b26777dc9cbe4a0c11919a02180adc3

Zobrazit plný text záznamu

Phase 2 study of gemcitabine, docetaxel, and doxorubicin in patients with advanced, unresectable, and/or metastatic sarcoma who have failed prior therapies

Autor: Neal Shiv Chawla, Doris Quon, Andrew Eugene Hendifar, William E. Mendanha, Xiao Zhang, Victoria S. Chua, Kamalesh Kumar Sankhala, Sant P. Chawla, Lita Fernandez

Publikováno v: Journal of Clinical Oncology. 33:10573-10573

10573 Background: Gemcitabine and docetaxel chemotherapy protocols have proven efficacy in the treatment of metastatic soft tissue sarcomas. Doxorubicin is also a commonly used treatment both as a ...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e260a9d96732817416f880e62aaf2c1e
https://doi.org/10.1200/jco.2015.33.15_suppl.10573

Zobrazit plný text záznamu

Phase I study of BPM 31510 in advanced solid tumors: Updated analysis of a novel treatment with promising activity

Autor: Niven R. Narain, Slava Akmaev, Victoria S. Chua, Andrew Eugene Hendifar, Doris Quon, Shen Luan, Arun S. Singh, Bartosz Chmielowski, David Chatman, Sant P. Chawla, Marita Okunnu, Paul Y. Song, Sandeep Nagre, John Patrick Mccook, Lita Fernandez, Rangaprasad Sarangarajan

Publikováno v: Journal of Clinical Oncology. 30:3015-3015

3015 Background: BPM 31510 is a novel small molecule that targets the metabolic machinery of the cancer microenvironment to reverse the aerobic glycolytic phenotype of cancer cells. Effector downstream signaling results in re-capitulation of BCL-2 me

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b6da59db0fc4d952d51780ad1f9ef3a8
https://doi.org/10.1200/jco.2012.30.15_suppl.3015

Zobrazit plný text záznamu

Phase I and II studies of intravenous Rexin-G as monotherapy for stage IVb gemcitabine-resistant pancreatic cancer

Autor: M. Fisher, Doris Quon, A. Saralou, Lita Fernandez, H. Bruckner, Frederick L. Hall, Erlinda M. Gordon, Shanta Chawla, C. S. Chua

Publikováno v: Journal of Clinical Oncology. 28:4149-4149

4149 Background: To evaluate (1) the safety and antitumor activity of Rexin-G, and (2) the cumulative toxicity and sustained efficacy of Rexin-G continuance in gemcitabine-resistant Stage IVb pancreas cancer. Methods: Fifteen patients were given esca

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9cbd4f3b5708d1044a8e8bda9c32b654
https://doi.org/10.1200/jco.2010.28.15_suppl.4149

Zobrazit plný text záznamu

Advanced phase I/II evaluation of tumor-targeted gene delivery: Intravenous retrovector encoding mutant anticyclin G1 as stand-alone therapy for chemotherapy-resistant bone and soft tissue sarcoma

Autor: Lita Fernandez, Victoria S. Chua, Erlinda M. Gordon, Frederick L. Hall, Kristen N. Ganjoo, Shanta Chawla, Doris Quon, A. Saralou

Publikováno v: Journal of Clinical Oncology. 28:10010-10010

10010 Background: To evaluate the safety and potential antineoplastic activity of intravenous (i.v.) retrovector encoding mutant anticyclin G1 (Rexin-G [R-G]) in chemoresistant bone and soft tissue...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::87daafe2c03e682c5c6de6ecb525afa8
https://doi.org/10.1200/jco.2010.28.15_suppl.10010

Zobrazit plný text záznamu

Evaluation of the safety and efficacy of pathotropic nanoparticles bearing a dominant negative cyclin G1 construct for chemoresistant osteosarcoma and other sarcomas: Phase I, II, and III studies

Autor: Lita Fernandez, Doris M Quon, Frederick L. Hall, W. C. Blackwelder, Shanta Chawla, Victoria S. Chua, Erlinda M. Gordon, A. Saralou

Publikováno v: Journal of Clinical Oncology. 27:10513-10513

10513 Background: (1) To evaluate the safety/anti-tumor potential of intravenous (i.v.) Rexin-G in chemotherapy-resistant sarcoma (Phase I/II), and (2) to confirm the efficacy/safety of i.v. Rexin-G in chemotherapy-resistant osteosarcoma (Phase II).

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c080b7bb5cf967ed9ac481ad3e1a47e2
https://doi.org/10.1200/jco.2009.27.15_suppl.10513

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání